Navigator Medicines Secures $100M Series A Financing and In-Licenses NAV-240
Slice of Healthcare Team
Aug 30, 2024
Key Highlights
- Navigator Medicines closes $100M Series A financing co-led by RA Capital Management and Forbion.
- In-licenses NAV-240 and OX40L-targeted portfolio from IMBiologics Corp.
- NAV-240 is a clinical-stage bispecific antibody targeting OX40L and TNFα, showing promise in treating inflammatory diseases.
- Board expands with the addition of Forbion and RA Capital leaders, strengthening strategic direction.
Source: Business Wire
Notable Quotes
“ NAV-240 has the potential to make an impact on patients living with autoimmune diseases, and our Series A funding will be pivotal in accelerating its development alongside other exciting programs within our pipeline. ”
Dr. Dana McClintock, CMO at Navigator Medicines
“ Given Forbion’s experience in building and guiding life sciences companies, partnering with Navigator allows NAV-240 to reach its full potential. ”
Wouter Joustra, General Partner at Forbion
“ This is an exciting opportunity to take a big step forward in therapeutic standards and transform patient care. ”
Dr. Andrew Levin, Partner and Managing Director at RA Capital Management
